Patent · US Active

Mutant 3-hydroxybutyrate dehydrogenase from alcaligenes faecalis as well as methods and uses involving the same

US10508267B2 · kind B2 · utility

1Cited by

8References

13Claims

0Family size

Assignees

Roche Diagnostics Operations, Inc. · US
Roche Diabetes Care, Inc. · US

Inventors

Peter Kratzsch · Penzberg, DE
Mara Boenitz-Dulat · Tutzing, DE
Daniela Beck · Penzberg, DE
Thomas Streidl · Seeshaupt, DE
Stacy Hunt DuVall · Indianapolis, US

Key dates

Filing date	Jun 21, 2018
Grant date	Dec 17, 2019
Priority date	—
Expiry date	Jun 21, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y101/0103
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present disclosure relates to a mutant 3-hydroxybutyrate dehydrogenase (3-HBDH) with improved performance relative to the wild-type 3-HBDH, a nucleic acid encoding the mutant 3-HBDH, a cell having the mutant 3-HBDH or the nucleic acid, and/or a method of determining the amount or concentration of 3-hydroxybutyrate in a sample. Also disclosed is the use of the mutant 3-HBDH for determining the amount or concentration of 3-hydroxybutyrate in a sample, and a device for determining the amount or concentration of 3-hydroxybutyrate in a sample.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.